Locations:
Search
Timing and type of side effects differ greatly from chemotherapy
Dedicated multidisciplinary teams support 84 ultra-rare cancers
Combination of olaparib and carboplatin results in complete durable response for a patient with BRCA2 and “BRCAness” mutations
Early communication between oncologists and ophthalmologist warranted
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
FDA-approved therapy offers promise for patients with castrate-resistant prostate cancer
The cornerstone of a successful doctor-patient relationship
Study shows encouraging safety results in rare type of adult brain cancer
Drug beats standard care for the treatment of relapsed or refractory ALL
Reflecting on our progress and potential
Researching and operationalizing a new therapy
Advertisement
Advertisement